Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Carbohydrate ingestion results in a fall in glucagon concentration in non-diabetic but not in diabetic individuals. To determine if, and the mechanism by which, lack of postprandial suppression of glucagon contributes to hyperglycaemia, nine subjects with insulin-dependent diabetes mellitus (IDDM) ingested 50 g of glucose containing both [2-3H] glucose and [6-3H] glucose on two occasions. [6-14C] glucose, insulin and low-dose somatostatin were infused intravenously at the same rates on both occasions. A basal glucagon infusion was started either at the same time ("constant glucagon") or 2 h following ("suppressed glucagon") glucose ingestion. This resulted in lower (p < 0.001) glucagon concentrations during the first 2 h of the suppressed than during the constant glucagon study days (63 +/- 1 vs 108 +/- 2 pg/ml). Lack of suppression of glucagon led to higher (p < 0.01) postprandial glucose concentrations (10.3 +/- 0.9 vs 8.1 +/- 0.7 mmol/l) and a greater (p < 0.02) integrated glycaemic response. The excessive rise in glucose was due to higher (p < 0.02) rates of postprandial hepatic glucose release during the constant than during the suppressed glucagon study days, whether measured using either [6-3H] glucose (2.6 +/- 0.2 vs 2.0 +/- 0.2 mmol.kg-1 per 6 h) or [2-3H] glucose (3.0 +/- 0.3 vs 2.4 +/- 0.2 mmol.kg-1 per 6 h) as the meal tracer. Glucose disappearance, initial splanchnic glucose clearance and hepatic glucose cycling did not differ on the two occasions. Thus, the present studies demonstrate that lack of postprandial suppression of glucagon, by increasing hepatic glucose release, contributes to hyperglycaemia in subjects with IDDM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have estimated that postprandial hyperglucagonemia may contribute to ~50% of the pathological increase in plasma glucose levels after glucose ingestion.145–147”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“Glucose turnover was calculated using Steele's non-steady-state equations [20].”
MethodThe Control of Glycogen Metabolism in the Liver
Hers, H. G. (1976) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.45.070176.001123 · Cited by 448
The control of glycogen metabolism in the liver
Hers, H. G., De Wulf, H., & Stalmans, W. (1970) · FEBS Letters · doi:10.1016/0014-5793(70)80569-5 · Cited by 414
Futile Cycles in the Metabolism of Glucose
(1976) · Current Topics in Cellular Regulation · doi:10.1016/b978-0-12-152810-2.50013-9 · Cited by 321 · cited 2×
“Hepatic glucose cycling refers to the concomitant uptake and release of glucose by the liver [27].”
BackgroundMethodFirth, R. G., Bell, P. M., Marsh, H. M., Hansen, I., & Rizza, R. A. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112467 · Cited by 280
Self-citationHyperglucagonemia and Blood Glucose Regulation in Normal, Obese and Diabetic Subjects
Sherwin, R. S., Fisher, M., Hendler, R., & Felig, P. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602262940901 · Cited by 252 · cited 2×
“Changes in portal venous insulin concentrations likely account for previous failures to detect an effect of glucagon on postprandial carbohydrate tolerance in non-diabetic volunteers '[7-9].”
BackgroundRole of glucagon in the pathogenesis of diabetes: The status of the controversy
Unger, R. H. (1978) · Metabolism · doi:10.1016/0026-0495(78)90291-3 · Cited by 216 · cited 6×
“This reciprocal relationship between glucose and gtucagon is abolished by diabetes mellitus [1, 2, 11].”
BackgroundInfluentialA simplified, colorimetric micromethod for xylose in serum or urine, with phloroglucinol.
Eberts, T. J., Sample, R. H., Glick, M. R., & Ellis, G. H. (1979) · Clinical Chemistry · doi:10.1093/clinchem/25.8.1440 · Cited by 199 · cited 1×
“, USA) and D-xylose by a colorimetric assay [18].”
MethodCURRENT TOPICS IN CELLULAR REGULATION
Stadtman, E. R., & Chock, P. B. (1996) · Shock · doi:10.1097/00024382-199609010-00016 · Cited by 179
Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans.
Dinneen, S., Alzaid, A., Miles, J., & Rizza, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116832 · Cited by 175 · cited 4×
“In non-diabetic individuals glucagon concentrations fall as glucose concentrations rise, and rise as glucose concentrations return toward preprandial levels [12-14].”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 101–189 of 189
Type 1 diabetes in mice and men: gene expression profiling to investigate disease pathogenesis
Yip, L., & Fathman, C. G. (2014) · Immunologic Research · doi:10.1007/s12026-014-8501-8 · Cited by 24
Dusaulcy, R., Handgraaf, S., Heddad-Masson, M., Visentin, F., Vesin, C., Reimann, F., Gribble, F. M., Philippé, J., & Gosmain, Y. (2015) · Endocrinology · doi:10.1210/en.2015-1725 · Cited by 25
“In diabetic patients glucagon release is not suppressed by increased glucose levels, and thus contributes further to postprandial hyperglycemia in both type 1 and type 2 diabetes (3,4).”
BackgroundGrøndahl, M. F. G., Keating, D. J., Vilsbøll, T., & Knop, F. K. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0967-z · Cited by 23
Adjunct therapies in treatment of type 1 diabetes
Goyal, I., Sattar, A., Johnson, M., & Dandona, P. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13078 · Cited by 18
“There is also concomitant α-cell dysfunction, with excess glucagon in both fasting and postprandial states worsening the hyperglycemia.(1) Insulin has been the mainstay of the treatment of this condition since its discovery nearly 100 years ago.”
BackgroundGlucagon and the Control of Appetite
Geary, N. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-61150-6_14 · Cited by 20
Magkos, F., Reeds, D. N., & Mittendorfer, B. (2022) · Physiological Reviews · doi:10.1152/physrev.00015.2022 · Cited by 21
Glucagon Clearance Is Preserved in Type 2 Diabetes
Grøndahl, M. F. G., Lund, A., Bagger, J. I., Petersen, T. S., Albrechtsen, N. J. W., Holst, J. J., Vilsbøll, T., Christensen, M., & Knop, F. K. (2021) · Diabetes · doi:10.2337/db21-0024 · Cited by 21
Extrapancreatic glucagon: Present status
Lund, A., & Knop, F. K. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.013 · Cited by 18
Possible Role of GLP-1 and Its Agonists in the Treatment of Type 1 Diabetes Mellitus
Issa, C. M., & Azar, S. T. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0291-6 · Cited by 15
Non-insulin pharmacological therapies for treating type 1 diabetes
Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1483339 · Cited by 18
Chowdhury, M. K. H., Wu, L. E., Coleman, J. L. J., Smith, N. J., Morris, M. J., Shepherd, P. R., & Smith, G. C. (2016) · Biochemical Journal · doi:10.1042/bcj20160121 · Cited by 18
Nyholm, B., Brock, B., Ørskov, L., & Schmitz, O. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.9.1641 · Cited by 17
Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes
Pillarisetti, S. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.009 · Cited by 15
Diabetes - Damages and Treatments
Rigobelo, E. C. (2011) · InTech eBooks · doi:10.5772/1823 · Cited by 17
Fang, J., Landersdorfer, C. B., Cirincione, B. B., & Jusko, W. J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9409-7 · Cited by 14
Grueter, C. A., Edgerton, D. S., Donahue, E. P., Vaughan, S., Chu, C. A., Sindelar, D. K., & Cherrington, A. D. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00043.2006 · Cited by 17
“A REDUCED DECREASE in endogenous hepatic glucose output (HGO) is a main cause of the postprandial hyperglycemia observed in type 2 diabetics (20, 36, 45, 59, 64).”
BackgroundSassa, M., Yamada, Y., Hosokawa, M., Fukuda, K., Fujimoto, S., Toyoda, K., Tsukiyama, K., Seino, Y., & Inagaki, N. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.009 · Cited by 14
“In addition, not only insulin-dependent diabetic patients but also noninsulin-dependent diabetic patients with hyperglycemia display paradoxical hyperglucagonemia, which contributes to postprandial hyperglycemia and glycemic instability [24,31].”
BackgroundDual‐hormone treatment with insulin and glucagon in patients with type 1 diabetes
Reiband, H. K., Schmidt, S., Ranjan, A. G., Holst, J. J., Madsbad, S., & Nørgaard, K. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2632 · Cited by 14
“glucagon levels contribute to the deterioration of glucose homeostasis by inducing excessive hepatic glucose release in the fasting state and diminished suppression of postprandial hepatic glucose production, which exacerbates postprandial hyperglycaemia [16].”
BackgroundPharmacological therapies to address obesity in type 1 diabetes
Casu, A., Bilal, A., & Pratley, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000555 · Cited by 16
“In parallel, a-cells are dysfunctional [28], resulting in a lack of glucagon suppression in the postprandial state [29], and insufficient release in response to hypoglycemia [30,31].”
BackgroundHong, F., Liu, L., Fan, R.-F., Chen, Y., Chen, H., Zheng, R., Zhang, Y., Gao, Y., & Zhu, J. (2013) · Translational research · doi:10.1016/j.trsl.2013.10.001 · Cited by 12
Preproglucagon Products and Their Respective Roles Regulating Insulin Secretion
Bethea, M. M., Bozadjieva-Kramer, N., & Sandoval, D. A. (2021) · Endocrinology · doi:10.1210/endocr/bqab150 · Cited by 12
Viloria, K., Hewison, M., & Hodson, D. J. (2021) · The Journal of Physiology · doi:10.1113/jp280890 · Cited by 15
Regulation of α‐cell glucagon secretion: The role of second messengers
Acreman, S., & Zhang, Q. (2021) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2021.06.001 · Cited by 14
“Not only does this lead to recurrent hypoglycaemia, a potentially life‐threatening medical condition that is currently the limiting factor in glycaemic management of the disease,(144) but also exacerbates hyperglycaemia.(145) Therefore, pharmacological interventions targeting α‐cell function will offer safer and bette…”
BackgroundCai, X., Lin, C., Yang, W., Nie, L., & Ji, L. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0171 · Cited by 12
“Type 1 diabetes mellitus (T1DM) is characterized by destruction of the pancreatic β-cells [1], resulting in severely impaired or absent insulin secretion combined with abnormal α-cell function, with excess glucagon in the fasting and postprandial state [2-4].”
BackgroundAlpha lipoic acid attenuates high-fructose-induced pancreatic toxicity
Topsakal, Ş., Özmen, Ö., Çankara, F. N., Yeşilot, Ş., Bayram, D., Özdamar, N. G., & Kayan, S. (2016) · Pancreatology · doi:10.1016/j.pan.2016.03.001 · Cited by 11
Role of the human kidney in glucose homeostasis
Meyer, C., & Gerich, J. E. (2000) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200002000-00003 · Cited by 11
Shu, S., Dai, A., Wang, J., Wang, B., Feng, Y., Li, J. X., Cai, X., Yang, D., Ma, D., Wang, M., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.036 · Cited by 11
Subramanian, V., Bagger, J. I., Harihar, V., Holst, J. J., Knop, F. K., & Villsbøll, T. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00278.2023 · Cited by 12
Damiano, F., Mercuri, E., Stanca, E., Gnoni, G. V., & Siculella, L. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.07.011 · Cited by 10
Takahashi, N., Chujo, D., Kajio, H., & Ueki, K. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12949 · Cited by 10
Function and survival of intrasplenic islet autografts in dogs
Burg, M. P. M. V. D., Guicherit, O. R., Jansen, J. B. �. �., Frölich, M. A., Lamers, C. B. H. W., Lemkes, H. H. P. J., Bruijn, J. A., & Gooszen, H. G. (1996) · Diabetologia · doi:10.1007/bf00400411 · Cited by 10
“Thus, hyperglucagonaemia and a concomitant reduction of the molar ratio of insulin and glucagon may have contr ibuted to the postprandial hyperglycaemia - via excessive postprandial hepatic glucose release, as found in insulin-dependent diabetes mellitus [34].”
BackgroundGlucagon-producing cells are increased in Mas-deficient mice
Braga, J. F., Dartora, D. R., Alenina, N. V., Bäder, M., & Santos, R. A. S. (2016) · Endocrine Connections · doi:10.1530/ec-16-0098 · Cited by 9
Lubaczeuski, C., Bozadjieva-Kramer, N., Louzada, R. A. N., Gittes, G. K., Leibowitz, G., & Bernal‐Mizrachi, E. (2023) · JCI Insight · doi:10.1172/jci.insight.162255 · Cited by 9
Ang, K. H., & Sherr, J. L. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1360862 · Cited by 11
“Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.”
BackgroundInvestigation of ginger (Zingiber officinale) aqueous extract as an anti-diabetic in vitro
Pakan, P., Lidia, K., & Riwu, M. (2021) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/913/1/012108 · Cited by 11
Yip, L., Alkhataybeh, R., Taylor, C., Fuhlbrigge, R., & Fathman, C. G. (2022) · Diabetes · doi:10.2337/db21-0948 · Cited by 8
Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_37-2 · Cited by 9
“Likewise, the lack of suppression of glucagon largely contributes to postprandial hyperglycemia in both T1DM (Dinneen et al. 1995) and T2DM (Shah et al.”
BackgroundEffects of hyperglycemia on glucose metabolism before and after oral glucose ingestion in normal men
Rigalleau, V., Beauvieux, M.-C., Gallis, J., Gin, H., Schneiter, P., & Tappy, L. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00407.2005 · Cited by 8
“Alternatively, plasma glucagon concentrations are normally suppressed after oral glucose (30), and the decline in glucagonemia contributes to inhibit glucose production (9).”
BackgroundDupre, J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2005.06.012 · Cited by 8
Disrupted glucose homeostasis and glucagon and insulin secretion defects in Robo βKO mice
Adams, M. T., Waters, B. J., Nimkulrat, S. D., & Blum, B. (2023) · The FASEB Journal · doi:10.1096/fj.202200705rr · Cited by 5
Nielsen, M. F. (2008) · PubMed · Cited by 6
Mechano-sensor Piezo1 inhibits glucagon production in pancreatic α-cells
Guo, W., Gao, L., Mo, H., Deng, H., Zhao, Y., & Xu, G. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167185 · Cited by 5
Thabit, H., Kumareswaran, K., Haidar, A., Leelarathna, L., Caldwell, K., Elleri, D., Allen, J. M., Nodale, M., Wilinska, M. E., Jackson, N. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4519 · Cited by 7
“Abnormal regulation of endogenous glucose production may also have a significant role in postprandial hyperglycemia (12).”
BackgroundMoore, M. C., DiCostanzo, C. A., Smith, M. S., Farmer, B., Rodewald, T., Neal, D. W., Williams, P. E., & Cherrington, A. D. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00184.2007 · Cited by 7
Metabolic Disturbances in Diabetes
Vella, A. V., & Rizza, R. A. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch13 · Cited by 5
Self-citationModeling diabetic alpha cell dysfunction using stem cell-derived alpha cells
Shrestha, S., Jennings, L. T., Knofczynski, K. R., Shivakumar, S. B., & Peterson, Q. P. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102504 · Cited by 8
“In diabetic individuals, alpha cells inappropriately secrete high amounts of glucagon when blood glucose levels are high (Dinneen et al., 1995), exacerbating hyper-glycemia (Jamison et al., 2011; Vergari et al., 2019; Asadi and Dhanvantari, 2021).”
InfluentialHædersdal, S., Lund, A., Nielsen-Hannerup, E., Maagensen, H., Forman, J. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0291 · Cited by 6
Basu, A., YADAV, Y. R., Carter, R. E., & Basu, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa241 · Cited by 8
Sybirna, N. O., Dziewulska-Szwajkowska, D., Barska, M., & Dżugaj, A. (2006) · Cell Biology International · doi:10.1016/j.cellbi.2006.03.008 · Cited by 5
“Destruction of b cells of Langerhans islets causes impaired insulin and amylin secretion, which results in reduced glucagon suppression (Pehling et al., 1984; Dinneen et al., 1995) and increased plasma glucagon concentrations (Gerich et al., 1976).”
BackgroundBiosynthesis, Secretion, and Action of Glucagon
Lefèbvre, P. J. (2003) · Wiley eBooks · doi:10.1002/0470862092.d0208 · Cited by 4
The Search for Glucagon Antagonists
Amatruda, J. M., & Livingston, J. N. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-61150-6_8 · Cited by 3
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
O’Donnell, H. K., & Driscoll, K. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816000-8.00003-7 · Cited by 5
Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_37 · Cited by 4
Metabolic Disturbances in Diabetes
Vella, A. V., & Rizza, R. A. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch15 · Cited by 3
Self-citationIncretin therapy in feline diabetes mellitus – A review of the current state of research
Haller, N., & Lutz, T. A. (2024) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2024.106869 · Cited by 4
Late Complications of Diabetes mellitus in the Republic of Uzbekistan
Ismailov, S. I., Berdykulova, D. M., & Хайдарова, Ф. А. (2004) · Heart Drug · doi:10.1159/000082188 · Cited by 2
Mott, J., Celly, C. S., Glock, R., & Gilor, C. (2024) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2024.106874 · Cited by 2
Editorial: Type 2 diabetes therapeutics: weight loss and other strategies
Magkos, F., & Mittendorfer, B. (2022) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000839 · Cited by 2
Obesity in Type 1 Diabetes Mellitus
Kalkan, G. E., & Özcan, B. A. (2023) · Wiley eBooks · doi:10.1002/9781119983347.ch9 · Cited by 2
A New Role for Glucagon: From Secondary Hormone to Key Player
De Fano, M., Malara, M., Rucco, S., Manco, M., Fanelli, C. G., Bolli, G. B., & Porcellati, F. (2025) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104233 · Cited by 1
Schernthaner-Reiter, M. H., & Schernthaner, G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1151783 · Cited by 1
Glucagon and the metabolic syndrome
Welch, A., & Vella, A. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00011-6 · Cited by 2
TRPM7 kinase regulates α-cell proliferation and glucagon production in mice
Boulassel, S., Schreier, P. C. F., Beck, A., Choi, H., Melyshi, A. M., Reinach, P. S., Duraj, M., Vinogradov, M., Suleimen, B., Berger, J., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102317 · Cited by 1
“These abnormalities highlight the central role of α -cell dysfunction in the pathophysiology of diabetes [3,21,22].”
Poole, E. M., Al-Issa, M., Dong, J., Shelp, G. V., Burns, S. E., Monk, J. M., Dyck, D. J., & Cho, C. E. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101389 · Cited by 2
“Stimulation of glucagon typically occurs by the fall in insulin in tandem with low glucose concentrations to mobilize hepatic glucose through the stimulation of glycogenolysis and gluconeogenesis [50], whereas loss of suppressive effects of glucagon may contribute to hyperglycemia [51].”
Zhu, W., Pan, L., Cui, X., Russo, A. C., RAY, R., Pederson, B., Wei, X., Lin, L. L., Torres, M., Hafner, H., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69928-6 · Cited by 1
“…Δ Hrd1 α TC cells were washed and sonicated in ice-cold lysis buffer (0.1M sodium acetate, pH 5.5, 1% Triton X-100, 50 µ M trans-epoxysuccinyl-L-leucylamido[4-guanidino] butane [E-64], 50 uM pepstatin, 1 mM phenylmethylsulfonyl fl uoride [PMSF]) and centrifuged at 10,000 × g at 4 °C for 10 minutes.”
InfluentialMolecular Mechanism Underlying the Intra-Islet Regulation of Glucagon Secretion
Kawamori, D., & Rohit, N. K. (2011) · InTech eBooks · doi:10.5772/24792 · Cited by 1
“…glucagon levels are often elevated in both type 1 and type 2 diabetes, thus are suggested to contribute to the development of insulin resistance (e.g. hepatic insulin resistance) and exacerbation of diabetes (Ahren and Larsson, 2001; Dinneen et al., 1995; Larsson and Ahren, 2000; Unger, 1978).”
BackgroundEffects of glucose-dependent insulinotropic polypeptide on glucagon
Christensen, M., & Knop, F. K. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000093 · Cited by 1
Lawaetz, T. W. H., Kücük, Z., Andersen, T. H., Jensen, A. K., & Johannesen, J. (2025) · Pediatric Diabetes · doi:10.1155/pedi/1633755 · Cited by 2
“Despite being inappropriate, it is a common phenomenon in T1D [35].”
Hvid, H., Brand, C. L., Hummelshøj, T., Jensen, S., Bouman, S. D., Bowler, A. N., Poulsen, B. R., Tiainen, P., Åkertröm, T., Demozay, D., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05828-w · Cited by 1
Type I Diabetes Mellitus (Insulin‐Dependent Diabetes Mellitus)
Rizza, R. A., Jensen, M. D., & Nair, K. S. (2001) · Comprehensive physiology · doi:10.1002/cphy.cp070236 · Cited by 4
Self-citationIslet Amyloid Polypeptide/GLP‐1/Exendin
Baggio, L. L., & Drucker, D. J. (2003) · Wiley eBooks · doi:10.1002/0470862092.d0209
GlucagonResponsetoOralGlucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia
Kramer, C. K., Borgo, C. A., Nostrand, P. V., Retnakaran, R. R., & Zinman, B. (2014)
Fast-to-fed shift in glucose homeostasis: clues to an earlier detection of human prediabetic states
Patarrão, R. S. (2010) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Cellular Immunological Mechanisms Contributing to Diabetes Pathogenesis
Radenkovic, M. (2016) · Lund University Publications (Lund University)
The metabolic effects of leptin therapy and glucagon suppression therapy in mouse models of diabetes
Neumann, U. H. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0348695
“In addition, hyperglucagonemia is present in many patients with type 1 and type 2 diabetes [67-71], and glucagon receptor”
BackgroundNelson, P. L. (2010) · Louisiana State University · doi:10.31390/gradschool_theses.3041
“This may explain the source of stimulation for the hyperglucagonemia seen in diabetics (Dinneen et al., 1995; Unger, 1978).”
BackgroundThe peptides profile changes in tissues under the condition of experimental obesity in rats
Krenytska, D., Yurchenko, A., Lipets, N., & Savchuk, О. (2019) · Bulletin of Taras Shevchenko National University of Kyiv Series “Psychology” · doi:10.17721/1728_2748.2019.77.21-26
The effect of lipids on glucoregulatory hormone actions
Grueter, E., & Alicia, C. (2006)
Role of Glucagon-like peptide-1 “Liraglutide” in Management of Type 1 Diabetes
Sehly, A. J. A., Altemani, R. F. H., Alharthi, Y. H. J., Alhwiti, A. G. S., Bedaiwi, A. A. A., Alqulayti, W. M., Alshuwaier, R. A. I., Alaql, A., & Ajwah, I. (2021) · International Journal of Pharmaceutical and Phytopharmacological Research · doi:10.51847/skbdqro7ng
Ravali, R. S., Lakshmi, K. S., Vijayakumar, T. M., & Kumar, J. S. (2021) · Obesity Medicine · doi:10.1016/j.obmed.2021.100359
Abu-Basha, E. A. H. (2002) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/rtd-180813-95
Biosynthesis, secretion, and action of glucagon
Lefèbvre, P. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch10 · Cited by 1
Bozadjieva, J. A. W. A. E. B.-M. N. (2013) · doi:10.3998/panc.2013.23
Obesity and insulin resistance: pathophysiology guiding precision therapy
Basu, A., & Basu, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00008-5
Fano, M. D., Porcellati, F., Fanelli, C. G., & Bolli, G. B. (2024) · il Diabete · doi:10.30682/ildia2401a
Babayeva, A., Coşkun, M., Yalçın, M. M., Aktürk, M., Törüner, F. B., Karakoç, M. A., & Altınova, A. E. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01367-9
“Lack of postprandial glucagon suppression contributes to fasting and postprandial hyperglycemia in patients with T1D [9].”
Metadata
- Authors
- Dinneen, S., Alzaid, A., Turk, D., & Rizza, R.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Dinneen, S.
- Venue
- Diabetologia
- Published
- 1995-03
- Volume
- 38
- Issue
- 3
- Pages
- 337-343
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2068377236
- Cited by
- 190
- References
- 38
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 8 · 2023: 5 · 2022: 5 · 2021: 13 · 2020: 8 · 2019: 3 · 2018: 7 · 2017: 12 · 2016: 10 · 2015: 10 · 2014: 11 · 2013: 5 · 2012: 7
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Mayo Foundation for Medical Education and Research
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 29953)
- National Center for Research Resources (RR-00585, M01RR000585)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon suppression, postprandial hyperglycemia, type 1 diabetes, hepatic glucose production, glucagon, glucose ingestion, somatostatin, glucose clearance
- MeSH terms
- Adult, Blood Glucose, Carbon Radioisotopes, Diabetes Mellitus, Type 1, Dietary Carbohydrates, Eating, Female, Glucagon, Glucose, Humans, Hyperglycemia, Infusions, Intravenous, Insulin, Kinetics, Liver, Male, Portal System, Radioisotope Dilution Technique, Somatostatin, Time Factors, Tritium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.